http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1
연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
양문정,전양환,한상익,한치화,엄현석 대한신경정신의학회 2000 신경정신의학 Vol.39 No.6
연구목적 : 암 환자에서 우울과 통증의 정도, 우울과 통증에 영향을 줄 수 있는 요인들을 조사하고, 우울과 통증사이에 어떤 연관이 있는지 알아보고자 하였다. 방 법 : 종양내과에 입원한 암 환자 25명(남자 : 10명, 여자 :15명)을 대상으로 하여 내과 병록지 거모, 환자 및 가족과의 면담을 시행하였다. 정신과적 진단은 DSM-IV진단 기준에 의하였으며, 우울의 정도는 Hamilton Rating Scale for Depression(HRSD)로 평가하였고 통증의 유무를 평가한 뒤, 통증이 있는 경우 Brief Pain Inventory(BPI)를 시행하여 통증의 강도(최대, 최소,평균,현재), 통증에 의한 기능 방해 정도, 진통제에 의한 호전정도를 점수로 평가하였다. 결 과 : 전체 환자중 주요 우울증이 32%(8명), 경도 우울증이 16%(4명), 적응장애가 16%(4명)이었다. HRSD점수는 통증의 최대강도, 평균강도, 현재강도, 통증에 의한 기능방해정도와 유의한 상관관계가 있었으나, 통증의 최소강도, 진통제에 의한 호전 정도와는 유의한 상관관계가 없었으며, 이환 기간과 HRSD점수 및 통증 점수 사이에도 유의한 상관관계가 없었다. 성별, 종교, 암의전이여부,병황의 인식 여부에 따라 HRSD점수와 통증 점수에 차이가 없었으나, 현재 미혼 또는 사별 상태에 있는 환자들에서 결혼하여 배우자가 있는 환자들보다 HRSD점수와 통증의 최소강도, 평균강도가 유의하게 높았다. 결 론 : 암환자에게서는 우울증과 통증이 있는 경우가 많았다. 우울증과 통증간에 밀접한 상관관계가 있음을 알수 있었다. 본 연구의 결과는 암 환자에서 우울증과 통증에 대한 보다 적극적인 평가와 개입이 이루어져야 함을 시사하는 것이다. Objective : This study was designed to evaluate how much depression and pain symptoms could be shown, what kink of factors affect them, and whether the correlation between them could be or not in patients with cancer. Methods : The subjects were composed of 25 patients with cancer who admitted a the department of oncology(male:10, female :15). We reviewed the medical record and interviewed patients and their family. A psychiatric diagnosis was made according to the criteria of the DSM-IV, and depressive symptoms were evaluated by Hamilton Rating Scale for Depression(HRSD). The intensity of pain(maximal, minimal, mean, present), disability due to pain, te effects of analgesics were measured by Brief Pain Inventory(BPI). Results : 32% of patients had major depressive disorders, 16% of patients had depressive disorders, NOS and 16% of the patients had adjustment disorders. The score of HRSD was significantly correlated wit the maximal intensity, mean intensity and present intensity of pain and disability due to pain, but not with minimal intensity and the effects of analgesics. Depression and pain were not correlated with duration of illness. Scores of depression and pain did not differ in sex, religion, metastasis, and the knowledge of illness. The widowed or unmarried patients showed significantly higher scores than patients living with the spouse in HRSD, minimal intensity and mean intensity of pain. Conclusion : In patients with cancer, depression and pain were highly prevalant. The relationship between depression and pain was shown in patients with cancer. These results suggest that more active evaluation and intervention of depression and pain should be carried out in patients with cancer.
Yang, Sanghwa,Jeung, Hei-Cheul,Jeong, Ha Jin,Choi, Yeon Ho,Kim, Ji Eun,Jung, Jae-Joon,Rha, Sun Young,Yang, Woo Ick,Chung, Hyun Cheol Elsevier 2007 Genomics Vol.89 No.4
<P><B>Abstract</B></P><P>To identify DNA copy number changes that had a direct influence on mRNA expression in gastric cancer, cDNA microarray-based comparative genomic hybridization (aCGH) and gene expression profiling were performed using 17?K cDNA microarrays. A set of 158 genes showing Pearson correlation coefficients over 0.6 between DNA copy number changes and mRNA expression level variations was selected. In an independent gene expression profiling of 60 tissue samples, the 158 genes were able to distinguish most of the normal and tumor tissues in an unsupervised hierarchical clustering, suggesting that the differential expression patterns displayed by this specific group of genes are most likely based on the gene copy number changes. Furthermore, 43 statistically significant (<I>P</I><0.01) genes were selected that correctly distinguished all of the tissue samples. The copy number changes detected by aCGH can be verified by fluorescence <I>in situ</I> hybridization and real-time polymerase chain reaction. The selected genes include those that were previously identified as being tumor suppressors or deleted in various tumors, including <I>GATA binding protein 4</I> (GATA4), <I>monoamine oxidase A</I> (MAOA), <I>cyclin C</I> (CCNC), and oncogenes including <I>malignant fibrous histiocytoma amplified sequence 1</I> (MFHAS1/MASL1), <I>high mobility group AT-hook 2</I> (HMGA2), <I>PPAR binding protein</I> (PPARBP), <I>growth factor receptor-bound protein 7</I> (GRB7), and <I>TBC1 (tre-2, BUB2, cdc16) domain family, member 1</I> (TBC1D1).</P>
Jung, Won‐,Gwan,Kim, Hee Sung,Lee, Ki Wook,Kim, Ye Eun,Choi, Dong Kyu,Jang, Bok‐,Il,Cho, Sung Hwoan,Choi, Cheol Young,Kim, Byeng‐,Hak,Joo, Yang‐,Ick John Wiley & Sons Ltd 2016 Journal of the World Aquaculture Society Vol.47 No.1
<P><B>Abstract</B></P><P>The effects on growth and body composition that result from tuna byproduct meal (TBM) substituted for fish meal in the diet of juvenile abalone, <I>Haliotis discus</I>, were determined. One thousand two hundred sixty juvenile abalone were randomly distributed into 18 70‐L plastic rectangular containers. Six experimental diets were prepared in triplicate. The TBM0 diet included 28% fish meal and 13% soybean meal as the protein source. Twenty‐five, 50, 75, and 100% of the fish meal were substituted with TBM. Finally, salted sea tangle was prepared. The essential amino acids, such as isoleucine, lysine, and valine, tended to decrease with the dietary substitution of TBM for fish meal in the experimental diets. The weight gain and specific growth rate (SGR) of abalone that were fed the TBM25 diet were higher than those of abalone that were fed the other diets. The crude protein content of the soft body of the abalone linearly decreased with the dietary substitution of TBM for fish meal. In conclusion, as much as 75% of the fish meal in the diet of abalone can be replaced with TBM without retardation in weight gain and SGR of the abalone when 28% fish meal was included.</P>